Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has emerged as a transformative option for weight management and heart disease prevention, with clinical trials showing up to 22% body weight reduction over 68 weeks. However, determining whether you should take semaglutide involves understanding FDA eligibility criteria, your personal health goals, and how your genetics influence treatment response. PlexusDx guides patients through this decision using precision health assessment.
Standard Eligibility Criteria for Semaglutide Weight Loss
The FDA approved semaglutide for chronic weight management in individuals with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or above who also have at least one weight-related condition such as high blood pressure, type 2 diabetes, or heart disease. Eligibility extends beyond BMI alone—your overall metabolic health, current medications, and medical history all factor into safe treatment candidacy. PlexusDx evaluates these factors during the initial consultation to ensure semaglutide aligns with your health profile.
Age and existing kidney or thyroid function matter significantly. Adults of all ages can benefit from semaglutide, but patients with severe kidney disease, untreated thyroid cancer, or a personal or family history of medullary thyroid carcinoma require careful consideration or alternative approaches. Your detailed medical questionnaire helps PlexusDx identify any contraindications before starting therapy.
Cardiovascular Benefits Beyond Weight Loss
The SUSTAIN-6 trial demonstrated that semaglutide reduces major adverse cardiovascular events by 26% in people with type 2 diabetes and established heart disease or high cardiovascular risk. This cardioprotective effect occurs partly through weight loss but also through direct actions on the heart and blood vessels, independent of glucose control. For patients whose primary motivation is heart health rather than weight loss alone, semaglutide offers dual benefit.
Blood pressure and cholesterol often improve within weeks of starting semaglutide, even before significant weight loss occurs. Patients with hypertension, prior heart attacks, or stroke histories frequently see treatment benefits extend far beyond the scale. PlexusDx considers cardiovascular risk factors when determining whether semaglutide is the optimal choice for your health goals.
How Genetic Testing Refines Your Semaglutide Candidacy
Not everyone responds to semaglutide equally. The PlexusDx Precision Peptide Genetic Test examines variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), FTO gene (rs9939609), and MC4R gene (rs17782313) to predict how your body will process and respond to GLP-1 therapy. Certain genetic patterns indicate stronger weight loss response, while others suggest better candidacy for dual-compound approaches like GLP-Squared.
This 14-pathway, 49-peptide analysis maps over 150 genetic insights relevant to appetite regulation and metabolic function. Adding the Precision Peptide Genetic Test ($99) after your first month of treatment allows PlexusDx to refine your therapy, ensuring you receive the compound and dosing strategy most likely to succeed for your unique biology. Genetic predisposition doesn't determine destiny—it informs strategy.
Practical Considerations for Starting Semaglutide at PlexusDx
PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies starting at $149 per month with flat pricing across commitment tiers—your dose may increase, but your price remains stable. Unlike many GLP-1 providers, PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorizations. HSA and FSA accounts cover compounded semaglutide, making treatment accessible regardless of insurance status.
The decision to start semaglutide should include a conversation about realistic timelines, potential side effects like nausea or appetite suppression, and commitment to ongoing lifestyle support. PlexusDx coordinates initial assessments, medication shipping, and follow-up monitoring to ensure you feel supported throughout your weight loss journey. If semaglutide alone doesn't achieve your goals, options like tirzepatide or GLP-Squared can be explored without switching providers.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need a BMI of 30 to take semaglutide with PlexusDx?
No. The standard FDA guideline is BMI 30 or higher, but patients with BMI 27 or above who have weight-related conditions like high blood pressure or diabetes also qualify. PlexusDx evaluates your complete health picture during your consultation, not just BMI alone.
Can semaglutide help my heart health even if I don't need to lose weight?
Yes. Clinical trials show semaglutide reduces heart attacks and strokes by 26% in high-risk patients, partly independent of weight loss. If you have cardiovascular disease or significant risk factors, semaglutide may be recommended by PlexusDx even at lower starting doses for heart protection.
What does the PlexusDx Precision Peptide Genetic Test tell me about semaglutide?
The test examines four key genes (GLP1R, GIPR, FTO, and MC4R) to predict how strongly you'll respond to semaglutide and whether a combination therapy might work better for you. This $99 add-on helps PlexusDx personalize your compound and dosing strategy after your first month.
Are there conditions that would make semaglutide unsafe for me?
Yes. Untreated thyroid cancer, severe kidney disease, or personal or family history of medullary thyroid carcinoma are contraindications. Pregnancy, recent pancreatitis, and uncontrolled gallbladder disease also require discussion with PlexusDx clinicians before starting.
How much does compounded semaglutide cost at PlexusDx?
Semaglutide injections start at $149 per month with flat pricing across all commitment tiers—your dose increases don't raise your monthly cost. No insurance required, HSA/FSA eligible, and PlexusDx serves all 50 states.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Soon After Ozempic Injection Do Side Effects Start?
Why Do People Lose Weight on Mounjaro?